Promising triple therapy targets rare, aggressive lymphoma
Disease control
Not yet recruiting
This study tests a new combination of three drugs (golidocitinib, pegaspargase, and an immunotherapy) as the first treatment for people with advanced NK/T-cell lymphoma, a rare and aggressive blood cancer. The goal is to see if this combination is safe and can shrink or eliminate…
Phase: PHASE2 • Sponsor: LIANG WANG • Aim: Disease control
Last updated May 01, 2026 11:14 UTC